INDIANAPOLIS, Jan. 29, 2013 /PRNewswire/ --
•Fourth quarter revenue declined 1 percent driven by Zyprexa patent expiration, largely offset by growth in other products.
•Fourth quarter earnings per share were $0.74 (reported), or $0.85 (non-GAAP).
•Full-year 2012 revenue declined 7 percent to $22.6 billion.
•Full-year 2012 earnings per share totaled $3.66 (reported), or $3.39 (non-GAAP).
•2013 guidance increased by $0.07 per share to reflect the estimated benefit from the delayed enactment of the American Taxpayer Relief Act of 2012.
•2013 earnings per share now expected to be in the range of $4.10 to $4.25 (reported), or $3.82 to $3.97 (non-GAAP).
Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2012.